Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 380

1.

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG.

Pharmacol Rev. 2008 Sep;60(3):358-403. doi: 10.1124/pr.107.00107. Review. Erratum in: Pharmacol Rev. 2008 Dec;60(4):582.

2.

Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, Höschl C.

CNS Drugs. 2006;20(5):389-409. Review.

PMID:
16696579
3.

Antipsychotic drug actions on gene modulation and signaling mechanisms.

Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA.

Pharmacol Ther. 2009 Oct;124(1):74-85. doi: 10.1016/j.pharmthera.2009.06.001. Epub 2009 Jun 21. Review.

PMID:
19540875
4.

[Neurobiological and pharmacologic aspects of atypical antipsychotic drugs].

Sümegi A.

Orv Hetil. 2009 Aug 16;150(33):1539-44. doi: 10.1556/OH.2009.28660. Review. Hungarian.

PMID:
19643718
5.

Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits.

Dean B, Scarr E.

Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):217-25. Review.

PMID:
15180482
6.

Conditioned avoidance response in the development of new antipsychotics.

Wadenberg ML.

Curr Pharm Des. 2010 Jan;16(3):358-70. Review.

PMID:
20109144
7.

Antipsychotic efficacy: relationship to optimal D2-receptor occupancy.

Pani L, Pira L, Marchese G.

Eur Psychiatry. 2007 Jul;22(5):267-75. Epub 2007 Apr 6. Review.

PMID:
17419008
8.

The complexity of the dopaminergic synapses and their modulation by antipsychotics.

Leuner K, Müller WE.

Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S15-20.

PMID:
16508891
9.

Drugs in development for the treatment of schizophrenia.

Emsley R.

Expert Opin Investig Drugs. 2009 Aug;18(8):1103-18. doi: 10.1517/13543780903066756. Review.

PMID:
19589093
10.

Preclinical findings with new antipsychotic agents: what makes them atypical?

Jackson DM, Ryan C, Evenden J, Mohell N.

Acta Psychiatr Scand Suppl. 1994;380:41-8. Review.

PMID:
7914047
11.

Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia.

Reynolds GP.

Acta Psychiatr Scand Suppl. 1994;380:36-40. Review.

PMID:
7914046
12.

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Miyamoto S, Duncan GE, Marx CE, Lieberman JA.

Mol Psychiatry. 2005 Jan;10(1):79-104. Review.

PMID:
15289815
13.

The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs.

Binder EB, Kinkead B, Owens MJ, Nemeroff CB.

Biol Psychiatry. 2001 Dec 1;50(11):856-72. Review.

PMID:
11743941
14.

The development of new drugs for the treatment of schizophrenia.

Cookson J.

Br J Hosp Med. 1987 Dec;38(6):542-8. Review.

PMID:
2893648
15.

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.

Meltzer HY, Huang M.

Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Review.

PMID:
18772033
16.

[Neurobiology in the neuropharmacology of antipsychotic drugs].

Tassin JP.

Encephale. 2006 Jan;32 Pt 2:S6-7. French. No abstract available.

PMID:
16800077
17.
18.

Current status of antipsychotic treatment.

Conley RR, Kelly DL.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):123-8. Review.

PMID:
12769630
19.

Targeting the dopamine D2 receptor in schizophrenia.

Seeman P.

Expert Opin Ther Targets. 2006 Aug;10(4):515-31. Review.

PMID:
16848689
20.

[New pharmacological approaches to the treatment of schizophrenia].

Uzbay IT.

Turk Psikiyatri Derg. 2009 Summer;20(2):175-82. Review. Turkish.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk